SHORLA ONCOLOGY
PharmaSHORLA ONCOLOGY is a pharmaceutical company focused on Oncology. Key products include IMKELDI.
SHORLA ONCOLOGY's Key Drugs
SHORLA ONCOLOGY's core commercial portfolio centers on IMKELDI, spanning Oncology — its most strategically important drugs approved in the last 15 years.
SHORLA ONCOLOGY's Recent FDA Approvals
SHORLA ONCOLOGY secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
SHORLA ONCOLOGY's Therapeutic Areas
SHORLA ONCOLOGY's approved drugs and pipeline span 1 therapeutic area, led by Oncology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
SHORLA ONCOLOGY's Top Competitors
SHORLA ONCOLOGY's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and Merck. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
SHORLA ONCOLOGY Pipeline Snapshot
Active clinical trials for SHORLA ONCOLOGY across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • IMKELDI leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2024-11-22
- Latest
- 2024-11-22
- Applications
- 1